An aging population and a rising incidence of vascular and metabolic diseases have increased, on a worldwide scale , the expansion of a debilitating problem that can worsen the quality of life: skin ulcers.

It is estimated that about 3% of the population over 60 is suffering from chronic ulcers of the lower limbs, reaching 5% in the over 80’s population (1).

It is furthermore estimated that about 3% of global medical expenses are related to the care of wounds (2).

These alarming figures have prompted THERESON, an Italian biomedical company, to invest, since  2011, in the development and distribution of Therapeutic Magnetic Resonance (TMR®).

THERESON therefore has devoted itself to clinical and scientific research to demonstrate the effectiveness of the treatment and to enhance  the operating principle of interaction between pulsed magnetic fields of particular form and frequency and damaged biological tissue, especially with the concomitant presence of chronic systemic diseases such as diabetes. Evidence was collected through biological tests, both in vitro and in vivo, two clinical trials on patients with Diabetic Foot and a biophysical model was developed to aid in understanding why the  TMR® pulsed fields, at low frequency and low intensity, were effective in improving circulation, in healing ulcers, and in reducing inflammation and pain perception.

Starting with Wound Care, an industry which spans various medical specialties, THERESON was able to deepen further possible applications of Therapeutic Magnetic Resonance (TMR®) outside the scope of its main application, as for example in the orthopaedic sector.

The analyses carried out in vitro indeed confirmed the ability of TMR® to stimulate the production of osteoblasts and osteogenic genes.

These first results, together with the observation of the benefits in terms of orthopaedic related diseases (e.g. acute and chronic inflammation, injury and surgical trauma, pain), have encouraged THERESON to enter into the orthopaedic sector.

A multidisciplinary work team was created to carry out all scientific activities, including a highly qualified THERESON staff able to coordinate and collaborate with university and hospital research activities, in particular:

  • University of Padua, Department of Biomedical Sciences, headed by Prof. Rizzuto, now Rector of the University, and Prof. Zavan, for cellular tests;
  • Cisanello University Hospital of Pisa, Diabetic Foot Department led by Prof. Alberto Piaggesi; Cà Foncello Hospital of Treviso, Dr Sambataro;Dr Pederzoli Nursing Home, Peschiera del Garda, Dr Nicoletti;
  • Institute for Theoretical Physics in Kiev, Prof. Larissa Brizhik (biophysical model).

The numerous data gathered has have been partly published and partly are awaiting publication.

THERESON wanted to make its technology available to patients, therefore it has been developed DIAPASON®, the first medical device that implements the TMR® method. THERESON has successfully begun to present it in Italy and abroad, thanks to collaboration with qualified partners in Wound Care and the Orthopaedic industry.

Improve the quality of life and restore health to people, using an effective therapeutic device easy to use for the patient at home: this is the vision of THERESON. 

Innovation, product quality, attention to the patient: our business paradigm.